Cyteir Therapeutics, Inc. Presents Ongoing Results from a Dose Expansion Cohort of CYT-0851 in Combination with Capecitabine in Advanced Platinum-Resistant Ovarian Cancer

Cyteir Therapeutics, Inc. presented ongoing results from a dose expansion cohort in its Phase 1 combination study of CYT-0851 with capecitabine in patients with platinum-refractory or -resistant...

Related Keywords

Massachusetts ,United States ,Boston , ,International Conference On Molecular ,Cyteir Therapeutics Inc ,Cyteir Therapeutics ,Expansion Results ,Monocarboxylate Transporter ,Platinum Resistant Ovarian ,Molecular Targets ,Cancer Therapeutics ,Markets ,